{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Number of participants with any adverse event","groups":[{"description":"Benign head and neck tumors will be treated with Stereotactic body radiotherapy\n\nstereotactic body radiotherapy: 14-16 Gray / 1 fraction OR 18-21 Gray / 3 fractions (6-7 Gray per fraction)OR 25-45 Gray / 5 fractions (5-9 Gray per fraction)","id":"OG000","title":"Benign Tumors"},{"description":"Malignant Head and Neck Tumors will be treated with Stereotactic body radiotherapy.\n\nStereotactic body radiotherapy: 8-12 Gray / 1 fraction OR 12-18 Gray / 3 fractions (4-6 Gray per fraction) OR 35-45 Gray / 5 fractions (7-9 Gray per fraction)","id":"OG001","title":"Unrescectable Malignant Tumors"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"9 patients did not have local control rate data reported. 3 patients were enrolled but never treated. 6 patients were lost to follow up.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Complication Rate","type":"PRIMARY","unitOfMeasure":"Participants"}